ISHL International Symposium on Hodgkin Lymphoma Program at a Glance

Saturday (03.10.2026) Sunday (04.10.2026) Monday (05.10.2026)
 


HL in Children and Adolescents

  • J. Flerlage
  • C. Mauz-Körholz

  1. Treatment Evolution in Pediatric Hodgkin Lymphoma: From Research to Real-World Impact

    • M. Mascarin

  2. Precision Medicine in Pediatric HL / Harmonized Pediatric HL Protocol in South Africa

    • J. Geel

  3. Oral Abstract Presentations


Closed Workshop on Grassroot Initiative in Classic Hodgkin Lymphoma
(Separate registration required)

  • R. Advani
  • P. Borchmann
  • P. Oyiro


Special Cases & Situations

  • P. Bröckelmann
  • J. Zijlstra

  1. HL in Pregnancy

    • A. Robertz

  2. Critical Organ Failure at Presentation

    • H. Tharmaseelan

  3. Anti-PD1 Tx in Pre-Existing Autoimmune Disease

  4. Workshop Report “Grassroot Initiative in Classic Hodgkin Lymphoma”

    • R. Advani
    • P. Oyiro


EHA-LYG/GHSG Joint Session: EHA Clinical Practice Guidelines in Lymphoid Malignancies - From Recommendations to Patient Care

  • I. Aurer
  • B. von Tresckow

  1. Large B-cell lymphomas

    • S. Leppä

  2. Mantle cell lymphoma

    • I. Aurer

  3. Follicular lymphoma

    • M. Hentrich

  4. HIV-related lymphomas

    • F. Damore

  5. Peripheral T-cell lymphoma

    • F. Damore

  6. New Therapeutic Concepts and Horizons in Lymphoma

    • C. Diefenbach


Joint-symposiums, Seminars and Workshops (⏲ parallel sessions)

  1. 🔒 Workshop: Workshop on ctDNA in HL
    (Separate registration required)

    • S. Alig
    • S. Borchmann
    • M. Pirosa
    • C. Steidl

  2. 🔒 Workshop: Individualization of Radiation Therapy for Hodgkin Lymphoma
    (Separate registration required)

    • H. Eich
    • J. Yahalom
Coffee Break
Coffee Break


New concepts for the treatment of B-cell lymphomas

by MSD Sharp & Dohme GmbH
  • B. von Tresckow

  1. DLBCL – The current and future role of ADCs in the context of T-cell engaging therapies

    • B. Chapuy

  2. cHL – Treatment strategies for PD-1 inhibition in the relapsed / refractory setting

    • B. von Tresckow


NLPHL

  • R. Hoppe
  • W. Klapper

  1. Clinical Implications of Growth Patterns

    • D. Eichenauer

  2. Treatment Strategies

    • J. Flerlage

  3. Oral Abstract Presentations
 
Coffee Break
Coffee Break


Translating ctDNA into clinical routine

  • S. Borchmann
  • M. Shipp

  1. Circulating Tumor DNA: New insights from the SWOG S1826 study.

    • M. Shipp

  2. Circulating Tumor DNA Analysis for Classification and MRD Assessment – Experience of the German Hodgkin Study Group

    • S. Borchmann

  3. Workshop Report

    • C. Steidl

  4. Oral Abstract Presentations


Relapsed & Refractory HL

  • C. Moskowitz
  • A. Sureda

  1. 2L Treatment of HL in Era of Novel Agents

    • A. Moskowitz

  2. Revisiting the Role of Stem Cell Transplantation in rrHL

    • B. von Tresckow

  3. Unmet Needs and Novel Treatment Approaches in >3L

    • M. Hutchings

  4. Oral Abstract Presentations
Coffee Break


Moving Targets: Rethinking Cellular Therapy Delivery in Aggressive B-Cell Lymphomas

by Miltenyi Biomedicine

  1. Opening and Framing

    • B. von Tresckow

  2. R/R DLBCL Treatment Landscape

    • G. Salles

  3. Difficult-to-Treat Patients in R/R DLBCL

    • I. Aurer

  4. CAR-T Delivery and Treatment Timing: Clinical Challenges and Opportunities

    • B. von Tresckow

  5. Future Directions in Cellular Therapy

    • A. Sureda

  6. Panel Discussion and Q&A
Lunch Break


Biology & Pathology

  • W. Klapper
  • C. Steidl

  1. The Biology of HRS Cells

    • R. Küppers

  2. Novel Insights Into the Microenvironment of Hodgkin Lymphoma

    • T. Aoki

  3. Oral Abstract Presentations


Best of ISHL14

  1. Best of ISHL14

    • R. Advani

  2. Farewell

    • P. Borchmann
Lunch Break
 


Early Stages

  • C. Diefenbach
  • H. Eich

  1. Personalized RTx: Focus on RTx Techniques and Late Effect Prediction Models

    • D. Cutter

  2. Just PD1-Inhibition? Early Insights from the GHSG INDIE Trial

    • P. Bröckelmann

  3. Debate: Should Novel Agents Be Integrated Into the Frontline Treatment of Early Stage Low Risk HL Patients?

    • G. Collins
    • C. Diefenbach

  4. Oral Abstract Presentations
Coffee Break


From Evidence to Experience: How Long-Term and Real-World Data for ADCETRIS® (brentuximab vedotin) May Inform Frontline Practice in Advanced Hodgkin Lymphoma

by Takeda Oncology
  • B. von Tresckow

  1. Enhancing Frontline Management in Advanced HL with BrECADD

    • O. Baiocchi

  2. Advancing HL Control and Fertility Preservation with BrECADD

    • E. Dann

  3. Optimizing Care in High-Risk HL with A+AVD

    • C. Burton
Coffee Break


Satellite Symposium 2

Coffee Break


Living Beyond Lymphoma

  • M. Büttner
  • A. Fosså

  1. Evaluating Late Effects of Contemporary Treatments - Competing Risks & Novel Approaches

    • C. Dietrich

  2. Uncertainties with Anti-PD1 & irAE in the First-Line Setting

    • P. Bröckelmann

  3. In Conversation with GHSG Patient Representatives: Building a Bridge Between Cancer Treatment and Everyday Life – Challenges After Lymphoma

    • K. Behringer
    • G. patient representatives

  4. Oral Abstract Presentations
Coffee Break


Opening Ceremony with Keynote Lecture & Awards

  1. Keynote Lecture: Changing treatment paradigms in B cell Lymphoma

    • G. Salles


Advanced Stages

  • P. Armand
  • G. Collins
  • M. Hertzberg

  1. Unmet Needs and Future Perspectives with BrECADD: Improving Outcomes of HD21

    • J. Ferdinandus

  2. Unmet Needs and Future Perspectives with Nivo-AVD: Unanswered Questions from SWOG S1826

    • A. Herrera

  3. Oral Abstract Presentations


Poster Session & Welcome Reception

 
 
  •   Main Program
  •   Satellite Symposium
  •   Scientific Session
  •   Joint Symposium/Seminar/Workshop